Interpace Biosciences Inc (ID) (IDXG)

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Interpace Biosciences Announces First Quarter 2026 Financial and Business Results

Q1 Revenue of $9.0 millionQ1 Income from Continuing Operations of $0.8 millionQ1 Thyroid volume year-over-year...

Form 8-K - Current report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results

Q4 and FY Revenue of $9.2 million and $38.7 millionQ4 and FY Income from Continuing Operations of $22.8 million...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Revenue Guidance and Simplification of Capital Structure

Preliminary 2025 thyroid testing revenue grew 21% over prior year Initial 2026 guidance of 16% growth in...

Form 8-K - Current report

Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners

PARSIPPANY, NJ, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCID: IDXG) (“Interpace” or...